MYGN Stock Recent News

Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad's molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).

SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD).

SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests. The liquid biopsy specialist said on Wednesday that blood samples from cancer patients would be processed using its Parsortix system, which isolates whole cancer cells circulating in the bloodstream.

SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025.

Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing

Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaffected cancer patients and launching the Precise MRD test for molecular residual disease. Full-year 2025 revenue guidance was raised to $818-$828 million, reflecting confidence in continued growth and expanding total addressable markets.

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Mark S. Verratti - Chief Operating Officer Matthew Scalo - Senior Vice President of Investor Relations Samraat S.

Myriad Genetics (MYGN) Q2 Revenue Up 6%